Johnson & Johnson
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IE
US
US
US
US
IN
US
US
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
Track Johnson & Johnson in real time with a live news feed covering Johnson & Johnson stock news, official press releases, company announcements, and an archive of historical Johnson & Johnson news. ...more
Loading news...
Loading more...
3:35 PM | Thursday | Aug 27, 2026
Sign in to download news snippet
Bitcoin exposure has powered early gains in the Porter & Company Porter Portfolio Index ETF (PCPP). The fund has grown to $23.9 million in assets less than three months after its launch, according to ETF Database data.
Read full articleNo data available for this time period.
Change the time range to see results.
Bitcoin exposure has powered early gains in the Porter & Company Porter Portfolio Index ETF (PCPP). The fund has grown to $23.9 million in assets less than three months after its launch, according to ETF Database data.
Read full article
Chasing a 7% blended yield across a $1.75 million portfolio sounds straightforward until you realize that loading up on the highest payers quietly destroys the very income stream you built. Three buckets solve the problem in ways that a single fund simply cannot.
Read full article
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
Read full article
China's drug regulator has approved Johnson & Johnson's oral pill for psoriasis, the company said on Thursday, intensifying competition in the world's second-largest pharmaceutical market with rivals including Bristol Myers Squibb and AbbVie.
Read full article
Imaavy can be used to treat patients aged 12 and older with warm autoimmune hemolytic anemia (wAIHA), a rare blood disease. It's the second FDA win for JNJ in as many months.
Read full article
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
Read full article
China's drug regulator has approved Johnson & Johnson's oral pill for psoriasis, the company said on Thursday, intensifying competition in the world's second-largest pharmaceutical market with rivals including Bristol Myers Squibb and AbbVie.
Read full article
Imaavy can be used to treat patients aged 12 and older with warm autoimmune hemolytic anemia (wAIHA), a rare blood disease. It's the second FDA win for JNJ in as many months.
Read full article
A nest egg of $840,000 sits right at the crossroads where dividends and annuities each look surprisingly compelling, and where the wrong choice quietly costs you tens of thousands of dollars over a 20-year retirement.
Read full article
VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.
Read full article
Retiring at 65 on dividends sounds straightforward until you realize the number you need today at 55 depends entirely on which yield tier you trust with your financial future, and the wrong choice leaves you no runway to recover.
Read full article
August is winding down, and income-focused investors have a narrow window to line up ex-dividend dates before the calendar turns.
Read full article
At $270.24, Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a hold.
Read full article
On CNBC's Squawk on the Street Monday morning, Jim Cramer said the tape has soured on the trade that carried the market for most of the past year.
Read full article
The yield you chase determines whether you need $1 million or $3.4 million, and the one that feels safest might quietly betray you a decade from now.
Read full article
No data available for this time period.
Change the time range to see results.